Iron%2520sucrose

# Iron sucrose ## Overview Iron sucrose is a parenteral iron complex used for the treatment of iron deficiency anemia. It provides iron to the reticuloendothelial system, where it is transferred to ferritin or hemosiderin and subsequently to transferrin for transport to erythroid marrow. ## Primary Indications * Iron deficiency anemia in patients undergoing chronic hemodialysis (receiving erythropoietin). * Iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease (ND-CKD). * Iron deficiency anemia in patients with dialysis-dependent chronic kidney disease (DD-CKD). ## Adult Dosing * **Hemodialysis (DD-CKD):** 100 mg administered intravenously (IV) during sequential dialysis sessions for a total dose of 1,000 mg over 10 sessions. * **Non-dialysis dependent (ND-CKD):** 200 mg IV per session for 5 sessions over 14 days (total 1,000 mg). * **Peritoneal dialysis (PD-CKD):** 300 mg IV at weeks 1 and 3, followed by 400 mg at week 5 (total 1,000 mg). * **Administration:** May be given as a slow IV push (undiluted) or as a diluted infusion. Refer to local institutional protocol for concentration maximums and infusion rates; typically, 100 mg is infused over at least 2–5 minutes. ## Pediatric Dosing * **Safety and efficacy are less established.** Use is generally off-label and requires institutional protocol alignment. * **Commonly reported dosing (ND-CKD/DD-CKD):** 0.5 mg/kg (up to 100 mg) per dose, administered once weekly for 10 weeks or as determined by iron deficit calculations. ## Dose Adjustments * **Hepatic Impairment:** No specific adjustments provided by manufacturer; monitor closely for iron overload. * **Renal Impairment:** Dosing is optimized for CKD; monitor serum ferritin and transferrin saturation (TSAT) to prevent iron toxicity. * **Elderly:** Use caution; initiate at the lower end of the dosing range due to higher frequency of decreased hepatic, renal, or cardiac function. ## Contraindications * Known hypersensitivity to iron sucrose or any component of the product. * Evidence of iron overload (hemochromatosis). * Anemias not caused by iron deficiency. ## Adverse Effects * **Common:** Hypotension, muscle cramps, nausea, vomiting, injection site reactions, and headache. * **Serious:** Anaphylaxis and severe hypersensitivity reactions (monitor closely during and for 30 minutes after infusion). ## Key Drug Interactions * **Oral Iron:** Parenteral iron can decrease the absorption of concurrently administered oral iron preparations. Avoid concomitant use; oral iron should be discontinued before initiating IV iron. ## Monitoring * **Laboratory:** Pre-treatment and periodic monitoring of Hemoglobin (Hgb), Hematocrit (Hct), Serum Ferritin, and TSAT. * **Clinical:** Blood pressure and heart rate during and immediately following administration. Monitor for signs of hypersensitivity (e.g., dyspnea, rash, angioedema). ## Clinical Pearls * **Iron Overload:** Do not administer if serum ferritin levels are elevated. High iron stores may lead to oxidative stress and organ damage. * **Infusion Reaction:** While rare, hypersensitivity reactions can occur. Ensure resuscitation equipment and staff trained in anaphylaxis management are available. * **Administration Speed:** Do not exceed the physician-ordered rate to minimize the risk of hypotension. * **Local Policy:** Always consult your institution's pharmacy policy or clinical order set, as specific infusion rates and dosing schedules for pediatric or off-label use vary significantly. *** **Educational Disclaimer:** This information is for educational purposes only. Always consult the most current FDA-approved prescribing information, your institution’s clinical guidelines, and the patient's electronic health record before prescribing or administering medication.